Why prostate cancer trial monitoring is essential in 2026
Prostate cancer is the second most common cancer in men worldwide, with over 300,000 new cases in the US annually. The treatment landscape for advanced and metastatic prostate cancer is one of the most commercially competitive in oncology — with approved agents from Janssen/J&J, Pfizer, Astellas, AstraZeneca, Bayer, and others competing across disease stages.
The competitive dynamics in 2026 prostate cancer trials center on several high-value questions:
- PSMA-targeted radioligand therapy — lutetium PSMA-617 (Pluvicto) approved for mCRPC; multiple follow-on programs exploring earlier disease settings, new isotopes (actinium-225), and combination partners; the most active mechanistic competition in prostate cancer
- Next-generation AR inhibitors — after enzalutamide, apalutamide, and darolutamide: novel AR degraders (ARV-110, KW-5626), allosteric inhibitors, and AR splice variant (AR-V7) targeting programs entering Phase 2
- PARP inhibitor combinations — olaparib + abiraterone and rucaparib approvals in HRRm patients; expanding to unselected populations and earlier settings; competitive with niraparib, talazoparib programs
- Bipolar androgen therapy (BAT) — high-dose testosterone paradoxically sensitizing AR-inhibitor-resistant tumors; academic and pharma combination programs entering trials
- Bispecific antibodies and CAR-T — PSMA × CD3 bispecifics (JNJ-63898081, CC-1 from Janssen), PSMA CAR-T programs from multiple academic and commercial groups
- Immunotherapy combinations — checkpoint inhibitors have largely failed in unselected prostate cancer; MSI-H and CDK12-mutant subtypes now being targeted in biomarker-selected trials
Track the prostate cancer trial landscape automatically
New prostate cancer trials register on ClinicalTrials.gov daily. Get a clean digest every morning.
Get Free AlertsWhat we monitor for prostate cancer
Our daily ClinicalTrials.gov pipeline can be configured for targeted prostate cancer monitoring:
- Condition keywords: "prostate cancer", "prostate adenocarcinoma", "mCRPC", "castration-resistant prostate cancer", "mCSPC", "nmCRPC", "biochemical recurrence"
- Mechanism/target keywords: "PSMA", "lutetium", "actinium", "AR degrader", "PARP inhibitor prostate", "bipolar androgen", "CDK12", "BRCA prostate"
- Disease stage: Keywords to distinguish localized, biochemically recurrent, nmCRPC, mCSPC, and mCRPC settings
- Phase filter: Phase 1 for early competitive intelligence, Phase 2/3 for near-term competitive threats
- Sponsor filter: Industry (commercial landscape) vs. all including NCI cooperative groups (SWOG, Alliance, ECOG)
The PSMA radioligand therapy competitive race
The approval of lutetium PSMA-617 (Pluvicto) by Novartis in 2022 for mCRPC opened one of the most competitive trial races in oncology. The competitive landscape now includes:
- Lutetium-177 PSMA programs: Novartis expanding Pluvicto into earlier disease stages (PSMAfore, TheraP-2 successors); Lantheus partnering with academic groups on PSMA theranostics
- Actinium-225 PSMA: Higher energy alpha-emitter; more potent but harder to manufacture; programs from Clarity Pharmaceuticals, ITM, RadioMedix and others; Phase 1/2 trials expanding
- PSMA-targeted ADCs: Multiple programs using PSMA as delivery vehicle for cytotoxic payloads instead of radioisotopes
- Combination strategies: RLT + PARP inhibitors, RLT + AR inhibitors, RLT + checkpoint inhibitors — dozens of combination trials now registering
For any team with prostate cancer commercial or investment interests, PSMA trial monitoring is now mandatory competitive intelligence.
New mechanisms entering Phase 3 (2025–2026)
The 2026 prostate cancer Phase 3 landscape includes several mechanisms that hadn't reached Phase 3 as recently as 2023:
Xaluritamig (Amgen) — STEAP1 × CD3 bispecific
STEAP1 is overexpressed in prostate cancer and is a validated target. Xaluritamig is a STEAP1-directed BiTE (bispecific T-cell engager) that redirects CD3+ T cells to kill STEAP1-expressing tumor cells. Amgen opened two Phase 3 trials in 2024: one in mHSPC with abiraterone (NCT07213674) and one in mCRPC versus cabazitaxel/AR-directed therapy (NCT06691984). This is the first STEAP1-targeted therapy to reach Phase 3 — a mechanism that had been in development for over a decade.
Opevesostat (Merck) — CYP11A1 inhibitor
Opevesostat (MK-5684) blocks CYP11A1, the first enzyme in the steroidogenesis pathway — further upstream than abiraterone (CYP17A1). The hypothesis: blocking steroidogenesis at the source eliminates both adrenal and intratumoral androgen synthesis, which may overcome resistance mechanisms that limit abiraterone/enzalutamide. Two Phase 3 trials (NCT06136624, NCT06136650) are actively recruiting in mCRPC patients who have progressed on one NHA. If successful, opevesostat would be the first CYP11A1 inhibitor approved in oncology.
Saruparib (AstraZeneca) — PARP1-selective inhibitor
Approved PARP inhibitors (olaparib, niraparib, rucaparib) are "pan-PARP" — they inhibit both PARP1 and PARP2. Saruparib (AZD5305) inhibits PARP1 selectively, which may preserve PARP2-dependent toxicity limitations. Two Phase 3 trials in prostate cancer are now recruiting (NCT06120491 in mCSPC; NCT06952803 in biochemical recurrence). The PARP1-selective hypothesis is one of the most contested in the next-generation oncology pipeline.
BNT324 (BioNTech) — mRNA cancer vaccine vs. docetaxel
BNT324 is BioNTech's personalized mRNA cancer vaccine in a head-to-head Phase 3 trial against docetaxel in mCRPC (NCT07365995). This is one of the first Phase 3 trials to test an mRNA therapeutic versus an established chemotherapy in solid tumors. The trial will be a significant data readout for the mRNA therapeutic hypothesis beyond infectious disease.
Prostate Cancer Phase 3 Pipeline — Selected Programs (2026)
The following table highlights selected Phase 3 prostate cancer programs active or recruiting on ClinicalTrials.gov as of March 2026. Grouped by mechanism.
| Drug / Sponsor | Mechanism | Setting | Trial ID | Status |
|---|---|---|---|---|
| Opevesostat (MK-5684) Merck |
CYP11A1 inhibitor | mCRPC after 1 NHA | NCT06136624 / NCT06136650 | Recruiting |
| Mevrometostat Pfizer |
EZH2/EZH1 inhibitor | mCRPC + mCSPC (3 Phase 3 trials) | NCT06629779, NCT06551324, NCT07028853 | Recruiting |
| Xaluritamig Amgen |
STEAP1 × CD3 BiTE | mCRPC vs cabazitaxel/AR-directed; mHSPC + abiraterone | NCT06691984 / NCT07213674 | Recruiting |
| Saruparib (AZD5305) AstraZeneca |
PARP1-selective inhibitor | mCSPC (NCT06120491); biochemical recurrence (NCT06952803) | NCT06120491 / NCT06952803 | Recruiting |
| AAA817 Novartis (Radiomedix/AAA) |
Actinium-225 PSMA RLT (alpha emitter) | mCRPC (after enzalutamide/abiraterone); mCSPC + ARPI | NCT06780670 / NCT06855277 | Recruiting |
| Lutetium PSMA-617 (Pluvicto) Novartis |
Lutetium-177 PSMA RLT | mCRPC PSMA+ (earlier line, pre-cabazitaxel) | NCT05939414 | Recruiting |
| Ifinatamab deruxtecan (I-DXd) Merck / Daiichi Sankyo |
B7-H3 targeting ADC | Metastatic prostate cancer | NCT06925737 | Recruiting |
| Niraparib + abiraterone Janssen |
PARP inhibitor + ARPI combo | mCSPC (biomarker-selected) | NCT04497844 | Active, NR |
| Olaparib + abiraterone AstraZeneca |
PARP inhibitor + ARPI combo | mCSPC (HRRm and unselected) | NCT05171816 / NCT03732820 | Active, NR |
| Talazoparib + enzalutamide Pfizer |
PARP inhibitor + ARPI combo | mCSPC DDR gene mutated | NCT04821622 | Active, NR |
| Capivasertib + abiraterone AstraZeneca |
AKT inhibitor + ARPI | mCSPC (PTEN-deficient / AKT pathway alterations) | NCT04493853 | Active, NR |
| Darolutamide + ADT Bayer (ECOG) |
ARPI (third-generation) | High-risk biochemical recurrence after prostatectomy | NCT04484818 | Active, NR |
| BMS-986365 Bristol-Myers Squibb |
Novel ARPI (AR degrader mechanism) | mCRPC vs investigator's choice NHA | NCT06764485 | Recruiting |
| Rezvilutamide (HRS-4357) Jiangsu HengRui |
AR antagonist (China-origin) | mHSPC — vs standard NHA | NCT07241416 | Recruiting |
Get daily prostate cancer trial alerts
Set your profile once. Receive a clean digest every morning with new prostate cancer trials and updates.
Get Free AlertsThe PARP Inhibitor Expansion — From HRRm-Selected to Unselected Populations
PARP inhibitors entered prostate cancer through the HRRm-selected (homologous recombination repair mutant) pathway: olaparib (PROfound), rucaparib (TRITON), and niraparib were approved for mCRPC patients with BRCA1/2 or other HRR gene alterations. The current Phase 3 wave is testing two questions simultaneously:
Question 1: Can PARP inhibitors combine with AR pathway inhibitors upfront in mCSPC?
The "combo upfront" hypothesis is now being tested at scale:
- Niraparib + abiraterone (Janssen, NCT04497844) — pivotal Phase 3 in mCSPC, HRRm and all-comers arms. Active, not recruiting.
- Olaparib + abiraterone (AstraZeneca, PROpel-2 successor) — two Phase 3 trials (NCT05171816, NCT03732820) in mCSPC, testing olaparib + abiraterone against abiraterone monotherapy. Active, not recruiting.
- Talazoparib + enzalutamide (Pfizer, TALAPRO-3) — mCSPC DDR gene mutated patients (NCT04821622). Active, not recruiting.
If multiple combos read out positively in mCSPC, the field will move PARP-based therapy earlier in the treatment sequence — potentially making unselected combination therapy the standard of care rather than a biomarker-selected option.
Question 2: Next-generation PARP1-selective inhibitors
AstraZeneca's saruparib (AZD5305) is a PARP1-selective inhibitor that may offer improved tolerability over pan-PARP agents. Two Phase 3 prostate cancer trials are now recruiting:
- NCT06120491 — saruparib vs. placebo in mCSPC (ARPIs backbone)
- NCT06952803 — saruparib vs. placebo in biochemically recurrent prostate cancer
The PARP1-selective hypothesis: PARP2 inhibition may drive much of the hematologic toxicity seen with olaparib/niraparib. Removing PARP2 inhibition could allow combination with full-dose AR inhibitors, broadening the eligible patient population beyond HRRm-selected patients.
Mevrometostat (Pfizer) — EZH2 Inhibition in Three Phase 3 Settings
Mevrometostat (PF-06821497) is an EZH2/EZH1 inhibitor — a mechanism targeting epigenetic dysregulation. EZH2 is overexpressed in advanced prostate cancer and has been associated with castration resistance. Pfizer has launched an unusually aggressive Phase 3 program with three concurrent trials:
- NCT06629779 — mevrometostat in mCRPC (second Phase 3 trial)
- NCT06551324 — mevrometostat in combination in mCRPC
- NCT07028853 — mevrometostat combination strategy
All three trials are recruiting as of 2026. The three-trial parallel Phase 3 strategy mirrors Pfizer's commitment to validating epigenetic targeting in castration-resistant disease — a mechanistically distinct approach from the dominant AR, PARP, and radioligand pathways.
Actinium-225 PSMA (AAA817, Novartis) — The Alpha Emitter Entering Phase 3
While lutetium PSMA-617 (Pluvicto) uses a beta-emitting isotope, AAA817 uses actinium-225 — an alpha-emitting radioisotope with a shorter range and higher energy, potentially effective in tumors where beta-particle radiation fails. Novartis has advanced AAA817 (Ac-225 PSMA) to Phase 3:
- NCT06780670 — AAA817 vs. standard of care in mCRPC patients who have progressed on androgen receptor pathway inhibitors. Recruiting.
- NCT06855277 — AAA817 + ARPI vs. standard of care in patients with metastatic castration-sensitive prostate cancer. Recruiting.
The actinium-225 Phase 3 program is the first large-scale comparison of alpha vs. beta PSMA radioligand therapy. If successful, Novartis would have two PSMA radioligand products (lutetium-177 Pluvicto + actinium-225 AAA817) serving different disease stages and patient populations.
Ifinatamab Deruxtecan (I-DXd) — B7-H3 ADC Entering Prostate Cancer
Ifinatamab deruxtecan (I-DXd, developed by Daiichi Sankyo and partnered with Merck/MSD) is an antibody-drug conjugate targeting B7-H3 — a checkpoint-related protein overexpressed in multiple solid tumors including prostate cancer. A Phase 3 trial opened in 2026 (NCT06925737) specifically in metastatic prostate cancer, marking the first major ADC Phase 3 entry into prostate cancer beyond established PSMA-directed platforms. B7-H3 is expressed broadly in late-stage prostate cancer, providing a potential mechanism for patients who are PSMA-negative or post-radioligand.
Who uses prostate cancer trial monitoring
- Oncology BD teams at pharma and biotech — tracking competitor PSMA, AR, and PARP programs across disease stages
- Prostate cancer-focused investors — monitoring pipeline milestones and competitive positioning
- CROs and nuclear medicine programs — identifying enrollment competition for radioligand therapy trials
- Prostate cancer patient advocacy (PCF, ZERO) — keeping patients informed about trial availability by disease stage
- Academic urologists and oncologists — monitoring commercial pipeline for collaboration and IIT opportunities
Monitor the prostate cancer pipeline daily
Set up your prostate cancer alert profile in 2 minutes. Cancel anytime.
Start Free — No Credit CardPricing
Free — $0 forever: 1 disease tracker, weekly digest, ClinicalTrials.gov monitoring. No credit card required.
Starter — $29/month: 5 disease/keyword profiles, daily digest, all phase and sponsor filters. Best for individual analysts.
Pro — $99/month: Unlimited profiles, daily digest, priority support. Best for BD and CI teams.
Frequently asked questions
How many prostate cancer clinical trials are active in 2026?
As of March 2026, there are 593 recruiting or active prostate cancer clinical trials on ClinicalTrials.gov, with 62 Phase 3 programs. The total prostate cancer trial database includes 799 studies in all statuses. Top sponsors include Novartis, AstraZeneca, Bayer, Merck, and Pfizer.
What is mevrometostat and why does it have three Phase 3 trials?
Mevrometostat (PF-06821497, Pfizer) is an EZH2/EZH1 inhibitor that targets epigenetic dysregulation in castration-resistant prostate cancer. Pfizer launched three concurrent Phase 3 trials (NCT06629779, NCT06551324, NCT07028853) in 2025–2026, testing mevrometostat in different mCRPC settings and combinations. The three-trial strategy reflects Pfizer's commitment to validating epigenetic targeting across multiple lines of therapy.
What is the difference between lutetium-177 PSMA and actinium-225 PSMA therapy?
Lutetium-177 (Pluvicto, Novartis) emits beta particles — lower energy, longer range, FDA-approved for mCRPC since 2022. Actinium-225 (AAA817, Novartis) emits alpha particles — higher energy, shorter range, potentially more cytotoxic per cell. Novartis has AAA817 in two Phase 3 trials (NCT06780670 in mCRPC; NCT06855277 in mCSPC + ARPI), making it the first large-scale Phase 3 comparison of alpha vs. beta PSMA radioligand therapy.
What is saruparib and how is it different from olaparib?
Saruparib (AZD5305, AstraZeneca) selectively inhibits PARP1, whereas olaparib inhibits both PARP1 and PARP2. The PARP1-selective hypothesis: PARP2 inhibition may drive hematologic toxicity seen with approved PARP inhibitors. By sparing PARP2, saruparib may allow broader combination with AR pathway inhibitors without dose-limiting toxicity. Two prostate cancer Phase 3 trials are recruiting: mCSPC (NCT06120491) and biochemical recurrence (NCT06952803).
How is prostate cancer trial monitoring different from ClinicalTrials.gov email alerts?
ClinicalTrials.gov basic alerts don't support phase filtering, sponsor filtering, disease-stage keywords, or mechanism-based searching. DataLookout delivers filtered daily digests — separating pivotal Phase 3 programs from early Phase 1 studies, industry from academic, and mechanism classes (PSMA, PARP, AR, epigenetic) from each other. Professional-grade signal extraction for BD teams and analysts.